'Conflict of Interest and Scientific Discovery' symposium to be held at Penn’s Perelman School of Medicine

Jun 1 2015

How can academic medical centers best manage the emerging issue of conflict of interest among scientists and physicians working to develop the next generation of treatments and cures? How do academic conflict of interest policies affect the process of scientific discovery? Exploring these questions and related issues will be at the heart of the "Conflict of Interest and Scientific Discovery" symposium organized by the Institute for Translational Medicine and Therapeutics at the University of Pennsylvania's Perelman School of Medicine. The meeting aims to stimulate conversation in an area that remains a barrier to translational therapeutics. Leaders from diverse disciplines--academia, venture capital, the pharmaceutical and biotech industries, government, private foundations, journal editors, and the media—will provide varied perspectives on conflict of interest during the day's events.

WHERE:

Perelman School of Medicine, University of Pennsylvania
Smilow Center for Translational Research, Rubenstein Auditorium and Commons Area
3400 Civic Center Blvd, Philadelphia, PA 19104
Please register online to attend or to view the live web stream.

WHEN:

Thursday, June 4, 2015, 11:45 a.m. to 4:00 p.m.
Friday, June 5, 2015, 8:30 a.m. to 4:00 p.m.
The full schedule is available online

WHAT:

National and international thought leaders and stakeholders representing the academy, private industry, government, among other groups.
Media Highlights

June 4th, 2:30 p.m. (session 2)Michael Rosenblatt, MD, Executive Vice President and Chief Medical Officer, Merck & Co.
The Academia-Industry Interface: Conflict of Interest/Alignment of Interest

June 4th, 2:30 p.m. (session 2): William Chin, MD, Executive Vice President of Science and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA)
Ethical Decision-Making in BioPharma: It's Not a Zero-Sum Innovation System

June 5th, 9:30 a.m. (session 3)Guy M. Chisolm, III, PhD, Former Director, Innovation Management & Conflict of Interest Program, Emeritus Professor, Department of Cellular and Molecular Medicine, Cleveland Clinic
Conflicts of Interest in Academic Medical Centers: Ethical Dilemmas in the Real World

June 5th, 10:30 a.m. Stakeholders in Conflicts of Interest Panel Discussion:

Communication with the Scientific Community: Howard Bauchner, MD, Editor-in-Chief, JAMA
Academia: Kathleen Giacomini, PhD, Professor and Co-Chair, Department of Bioengineering and Therapeutic Sciences; Professor, Departments of Biopharmaceutical Sciences, Pharmaceutical Chemistry, and Cellular & Molecular Pharmacology, University of California, San Francisco
Compliance/Legal: Laurel Fleming, JD, Director, Health System Compliance & Chief Privacy Executive, Northwestern Memorial HealthCare
Patient Engagement Advocate: Margaret Anderson, Executive Director, FasterCures

June 5th, 1:00 p.m. Stakeholders in Conflicts of Interest Panel Discussion - 2

Academia: George Loewenstein, PhD, Herbert A. Simon Professor of Economics and Psychology, Carnegie Mellon University
Biotech: Dennis Liotta, PhD, Executive Director Emory Institute for Drug Development (EIDD)/ Samuel Candler Dobbs Professor of Chemistry, Emory University
Communication with the Public: Katie Thomas, the New York Times
Academia: James Wilson, MD, PhD, Professor of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
NIH: Sally J. Rockey, Deputy Director for Extramural Research, National Institutes of Health

Source: University of Pennsylvania